Clinical Trial Update: Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial assessed ovarian function suppression with tamoxifen or exemestane versus tamoxifen alone in premenopausal women with hormone-responsive breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Progesterone Receptor-positive Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: ETOP IBCSG Partners Foundation | Conditions: Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor | Phase 3 | Status: COMPLETED | Results posted: 2016-09-22